GenSci & IsoTis shareholders approve merger:
This article was originally published in Clinica
Executive Summary
99.9% of Canadian firm GenSci's shareholders and 99.75% of IsoTis's have voted in favour of the merger of Swiss-Dutch IsoTis and GenSci OrthoBiologics, of Irvine, California. The group is hoping to double its combined revenues and reach profitability by 2005. In the six months to the end of June 2003, the two companies had combined sales of $11.8m and a net loss of $12.6m. The transaction is expected to close on October 27, and is dependent on the California Bankruptcy Court approving GenSci OrthoBiologics' emergence from Chapter 11 bankruptcy protection.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.